Immunosuppression in Burkitt's lymphoma. I. Cutaneous reactivity to recall antigens: alterations induced by a tumour burden and by BCG administration.
D000937:Antigen-Antibody Reactions; D001500:BCG Vaccine / Q000494:pharmacology; D002051:Burkitt Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D002176:Candida albicans / Q000276:immunology; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D009108:Mumps Vaccine / Q000494:pharmacology; D011379:Prognosis; D012882:Skin Tests; D013299:Streptodornase and Streptokinase / Q000494:pharmacology; D013997:Time Factors; D014373:Tuberculin / Q000494:pharmacology
D001500:BCG Vaccine; D009108:Mumps Vaccine; D014373:Tuberculin; D003520:Cyclophosphamide; D013299:Streptodornase and Streptokinase